Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α

Oncotarget

Volumn 6, Issue 6, 2015, Pages 4428-4439

  Elkord, Eyad ^a,b,c   Burt, Deborah J ^a   Sundstedt, Anette ^d   Nordle, Örjan ^d   Hedlund, Gunnar ^d   Hawkins, Robert E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^c UNIVERSITY OF SALFORD   (United Kingdom)

^d Active Biotech Research AB   (Sweden)

Author keywords

ABR 217620; Immune analysis; Naptumomab estafenatox; Overall survival; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CD45RO ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; L SELECTIN; NAPTUMOMAB ESTAFENATOX; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ENTEROTOXIN; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ANTIGEN BINDING; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; VERY ELDERLY; ADOLESCENT; BLOOD; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DRUG EFFECTS; FLOW CYTOMETRY; IMMUNOLOGY; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; T LYMPHOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; ENTEROTOXINS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOCONJUGATES; INTERFERON-ALPHA; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84924255334     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2922     Document Type: Article

References (21)

1. Abe H, Kamai T. Recent advances in the treatment of metastatic renal cell carcinoma. Int J Urol. 2013; 20:944-55.
2. Eisen T, Hedlund G, Forsberg G, Hawkins R. Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014; 16:370.
3. Dohlsten M, Abrahmsén L, Björk P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NR, Förberg C, Lind P, Kalland T. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci U S A. 1994; 91:8945-9.
4. Dohlsten M, Hedlund G, Akerblom E, Lando PA, Kalland T. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A. 1991; 88:9287-91.
5. Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci U S A. 1995; 92:9791-5.
6. Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A. Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. J Clin Oncol. 2004; 22:602-9.
7. Shaw DM, Connolly NB, Patel PM, Kilany S, Hedlund G, Nordle O, Forsberg G, Zweit J, Stern PL, Hawkins RE. A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007; 96:567-74.
8. Forsberg G, Skartved NJ, Wallén-Ohman M, Nyhlén HC, Behm K, Hedlund G, Nederman T. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother. 2010; 33:492-9.
9. Griffiths RW, Gilham DE, Dangoor A, Ramani V, Clarke NW, Stern PL, Hawkins RE. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer. 2005; 93:670-7.
10. Elkord E, Shablak A, Stern PL, Hawkins RE. 5T4 as a target for immunotherapy in renal cell carcinoma. Expert Rev Anticancer Ther. 2009; 9:1705-9.
11. Hedlund G, Eriksson H, Sundstedt A, Forsberg G, Jakobsen BK, Pumphrey N, Rödström K, Lindkvist-Petersson K, Björk P. The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity. PloS one. 2013; 8:e79082.
12. Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27:4116-23.
13. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 2006; 107:628-36.
14. Harrop R, Treasure P, de Belin J, Kelleher M, Bolton G, Naylor S, Shingler WH. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). Cancer Immunol Immunother. 2012; 61:2283-94.
15. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011; 12:1125-33.
16. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012; 13:827-37.
17. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, Philip T, Favrot M. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52:3317-22.
18. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C, Blay JY. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol. 2004; 22:2371-8.
19. Thiounn N, Pages F, Flam T, Tartour E, Mosseri V, Zerbib M, Beuzeboc P, Deneux L, Fridman WH, Debré B. IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett. 1997; 58:121-4.
20. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9:798-809.
21. Kim HJ, Cantor H. The Path to Reactivation of Antitu-mor Immunity and Checkpoint Immunotherapy. Cancer Immunol Res. 2014; 2:926-36.